BrainsWay’s SWIFT Deep TMS Cuts Treatment Visits 70%, Yields 78% Remission
BrainsWay’s FDA-cleared SWIFT Deep TMS protocol cut the acute depression treatment from 20 visits to six half days, reducing clinic visits by 70% while achieving an 87.8% response rate and 78.0% remission rate. Median time to remission improved to 21 days versus 28 days under the standard protocol.
1. Clinical Trial Outcomes
In a large multisite non-inferiority trial, BrainsWay’s SWIFT accelerated Deep TMS achieved an 87.8% response rate and a 78.0% remission rate on the HDRS-21 scale, with a median remission time of 21 days versus 28 days for the standard protocol.
2. Protocol Efficiency
The SWIFT protocol compresses the acute treatment phase from 20 daily sessions over four weeks to six half-day sessions, followed by four weekly maintenance visits, reducing clinic attendance by roughly 70%.
3. Patient-Reported Improvements
Patient-reported outcomes showed a 32-point improvement in quality-of-life scores and a decline in severe functional impairment from up to 100% at baseline to 15–17% post-treatment, with approximately 60% of participants returning to normal-range functioning.
4. Adoption and Market Impact
Administrative barriers are easing as leading payers remove prior authorization for Deep TMS, setting the stage for wider adoption of SWIFT’s accelerated protocol and potential revenue growth for BrainsWay.